It has been informed that a drug potential of treating Type 2 diabetes has got approval by the federal court on Friday. The drug manufacturers have been seeking approval from past many years.

The drug, Bydureon, is produced by the Amylin Pharmaceuticals. A patient suffering from the type 2 diabetes is required to inject the drug just once in a week. However, the other medications available in the clinics or markets are required to be taken every day.

The approval of the drug would through much competition to the Novo Nordisk's drug Victoza. The drug Victoza is a similar drug which has to be injected every day by the type 2 diabetic patient. It has been informed that the Novo Nordisk has recruited a celebrity chef Paula Deen for promoting its drug. The decision of recruiting Paula Deen was taken amidst the growing competition in the market.

Amylin Pharmaceuticals had been applying for the approval of the drug Bydureon for past two years. Since 2010, the Pharmaceuticals have been facing rejection by the FDA. But its recent approval has brought a huge smile on the faces of its customers.

Following the announcement of approval, the shares of the Amylin Pharmaceuticals rose by 1.7%. The analysts are of the view that the approval would lead to sales of $1 billion. However, the safety concerns over the thyroid and pancreatitis is causing problems to the Amylin Pharmaceuticals.

However, there are many who are of the view that the Bydureon would bring a revolution as it would substitute all the diabetes injections. Since, a person with type 2 diabetes is required to take just one injection of Bydureon, it would prove one of the most convenient ways to treat type 2 diabetes.